title: Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells.
abstract: mTOR inhibitors have potent antiangiogenic and anti-lymphangiogenic effects in addition to their growth inhibitory effects in head and neck squamous cell carcinoma (HNSCC). Lymphatogenous spread is much more predominant in HNSCC than hematogenous spread and significantly decreases survival. In this study we evaluated the effects of rapamycin on targeting tumor-stroma crosstalk in HNSCC. HNSCC tumor cells (FaDu) and human lymphatic endothelial cells (HMEC-1A) were co-cultured in various combinations using transwell cell culture inserts to study tumor-stroma crosstalk and the effects of mTOR inhibitor rapamycin. Levels of growth factors and cytokines in cell culture media were measured using Milliplex bead immunoassay (EMD Millipore) and ELISA assay (R&D Systems). We found that conditioned media collected from tumor cells or co-culture with tumor cells significantly increased the invasiveness of lymphatic and blood vascular endothelial cells (P<0.05), while there was no effect of conditioned media collected from endothelial cell cultures or co-culture with endothelial cells on tumor cell invasiveness. There was a significant effect of rapamycin on both baseline and tumor cell stimulated invasiveness of endothelial cells (P<0.05). Importantly the level of IL-6 secreted in media increased significantly in tumor-endothelial cell co-culture compared to monocultures. Rapamycin significantly suppressed secretion of IL-6 by tumor cells (P<0.05). Thus, HNSCC cells produce chemotactic stimuli that promote endothelial cell invasion toward tumor cells that can stimulate lymphangiogenesis. Rapamycin effectively reverted the stimulatory effect of IL-6 secreted by tumor cells on endothelial cell invasiveness.
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, LSUHSCShreveport, LA, USA; Feist-Weiller Cancer Center, LSUHSCShreveport, LA, USA.
authors.forename: Oleksandr
authors.initials: O
authors.lastname: Ekshyyan
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, LSUHSCShreveport, LA, USA; Feist-Weiller Cancer Center, LSUHSCShreveport, LA, USA.
authors.forename: Alok R
authors.initials: AR
authors.lastname: Khandelwal
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, LSUHSCShreveport, LA, USA; Feist-Weiller Cancer Center, LSUHSCShreveport, LA, USA.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Rong
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, LSUHSCShreveport, LA, USA; Feist-Weiller Cancer Center, LSUHSCShreveport, LA, USA.
authors.forename: Tara
authors.initials: T
authors.lastname: Moore-Medlin
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, LSUHSCShreveport, LA, USA; Feist-Weiller Cancer Center, LSUHSCShreveport, LA, USA.
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Ma
authors.affiliation: Department of Cellular and Molecular Physiology, LSUHSC Shreveport, LA, USA.
authors.forename: Jonathan Steven
authors.initials: JS
authors.lastname: Alexander
authors.affiliation: Department of Otolaryngology/Head and Neck Surgery, LSUHSCShreveport, LA, USA; Feist-Weiller Cancer Center, LSUHSCShreveport, LA, USA.
authors.forename: Cherie-Ann O
authors.initials: CO
authors.lastname: Nathan
keywords: Head and neck squamous cell carcinoma; Interleukin-6; crosstalk; lymphangiogenesis; mTOR inhibitors